Bristol Myers Squibb (CELG-RI) Payables (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Payables of $4.2 billion for Q2 2026, down 23.38% year-over-year from $5.4 billion in Q2 2025, and down 1.79% quarter-over-quarter from $4.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Payables (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Payables for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Payables fell 23.38% year-over-year to $4.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (down 23.38% YoY), while the FY2025 annual figure was $3.6 billion, down 0.75% from the prior year.
- Payables declined to $4.2 billion in Q2 2026 per CELG-RI's latest filing, from $4.2 billion in the prior quarter.
- Across five years, Payables topped out at $5.4 billion in Q2 2025 and bottomed at $2.6 billion in Q3 2022.
- Historically, Payables has averaged $3.5 billion across 5 years, with a median of $3.5 billion in 2024.
- Annual changes were most pronounced in 2025 — Payables jumped 44.68% — and 2026, when it decreased 23.38%.
- Bristol Myers Squibb's Payables stood at $3.0 billion in 2022, then advanced by 7.2% to $3.3 billion in 2023, then grew by 10.52% to $3.6 billion in 2024, then slipped by 0.75% to $3.6 billion in 2025, then grew by 16.31% to $4.2 billion in 2026.
- Business Quant data shows CELG-RI's Payables at $4.2 billion in Q2 2026, $4.2 billion in Q1 2026, and $3.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 469.99 Bn | 463.42 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 303.26 Bn | 295.57 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.45 Bn | 252.55 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.73 Bn | 222.74 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 182.06 Bn | 178.88 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 4.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.16 Bn |
| Mar 31, 2026 | 4.23 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Sep 30, 2025 | 4.29 Bn |
| Jun 30, 2025 | 5.43 Bn |
| Mar 31, 2025 | 4.00 Bn |
| Dec 31, 2024 | 3.60 Bn |
| Sep 30, 2024 | 3.47 Bn |
| Jun 30, 2024 | 3.75 Bn |
| Mar 31, 2024 | 3.54 Bn |
| Dec 31, 2023 | 3.26 Bn |
| Sep 30, 2023 | 2.81 Bn |
| Jun 30, 2023 | 3.07 Bn |
| Mar 31, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.04 Bn |
| Sep 30, 2022 | 2.60 Bn |
| Jun 30, 2022 | 2.88 Bn |
| Mar 31, 2022 | 2.94 Bn |
| Dec 31, 2021 | 2.95 Bn |
| Sep 30, 2021 | 2.70 Bn |